Please login to the form below

Not currently logged in
Email:
Password:

non-small cell lung cancer

This page shows the latest non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

Neoantigen player Achilles gets OK for first clinical trial

Neoantigen player Achilles gets OK for first clinical trial

trial of its candidate for advanced non-small cell lung cancer (NSCLC) after getting a green light from the MHRA. ... It’s operating in a busy field in immuno-oncology, with a clutch of companies focusing on neoantigens as a way to tackle cancer using

Latest news

  • EU approval for Opdivo combo in renal cell cancer EU approval for Opdivo combo in renal cell cancer

    This follows US approval last year, and is the first Immuno-Oncology (IO) combination therapy for patients with this type of cancer in the European Union. ... This is necessary as it now looks impossible for Opdivo to catch its big rival Keytruda in the

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    studies of NKTR-214 in front-line and second-/third-line non–small-cell lung cancer (NSCLC) in the second-quarter, and are now working on 20 indications across nine tumour ... Robin said that studies are now underway or planned for the CD122-biased

  • AZ still sees route to approval for Imfinzi in MYSTIC trial AZ still sees route to approval for Imfinzi in MYSTIC trial

    New analysis shows opportunity in NSCLC. AstraZeneca isn’t giving up on its aspirations for Imfinzi in first-line non-small cell lung cancer (NSCLC), and against all odds thinks the ... A high TMB reading indicates more markers on the cancer cell

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    a wave of new PARP inhibitors coming through the pipeline, including Pfizer’s Talzenna (talazoparib) which was approved a few weeks ago for advanced breast cancer. ... The phase 2 JASPER trial, for example, pairs Zejula with TSR-042 in first-line

  • NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

    But it is only available via the CDF for now. England's cost effectiveness watchdog NICE has recommended BMS' Opdivo  as an adjuvant treatment for skin cancer, reversing its initial decision ... That's great news for BMS, which has fallen far behind

More from news
Approximately 1 fully matching, plus 518 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... For patients with previously chemo-treated advanced non-small cell lung cancer, Opdivo reduced the risk of death in

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... Its Imfinzi has secured the first-ever US and EU approval in

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting,” says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... It will also be interesting to see how gene

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics